ClinicalTrials.gg
CompletedNCT02532634RAPAUpdated May 11, 2018

Ramosetron, Aprepitant, and Dexamethasone Versus Palonosetron, Aprepitant, and Dexamethasone

A Phase 4 interventional study of ramosetron, aprepitant, dexamethasone and palonosetron, aprepitant, dexamethasone in Cancer and Tumors, sponsored by Kangdong Sacred Heart Hospital. Completed at 10 sites in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2018-05-11.

Sponsored by Kangdong Sacred Heart Hospital · Phase 4, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
292
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Study summary

The purpose of this study is to compare the anti-emetic effect of ramosetron plus aprepitant and dexamethasone with palonosetron plus aprepitant and dexamethasone in patients receiving highly emetogenic chemotherapy.

Read the detailed description

Currently, palonosetron is the clinically preferred antiemetic for Chemotherapy-induced nausea and vomiting (CINV).However the best 5-hydroxytryptamine 3 receptor (5-HT3R) antagonists for use in a triple drug combination for high emetogenic chemotherapy(HEC) has not yet been determined in randomized trials. Previous anti-emetic guidelines stated that the anti-emetic activities of 5-HT3R antagonists were similar at equivalent doses. Based on the meta-analysis of various 5-HT3R antagonists in double regimens, the NCCN guideline has suggested palonosetron as a preferred 5-HT3R antagonist in the triple antiemetic drug combination. But in Asia, RAD is one of the most popular treatments for HEC-treated cancer patients. However, the lack of clinical studies has precluded the recommendation of RAD as a standard regimen for HEC-induced CINV. In two previous studies conducted in Korea, RAD regimen showed significant efficacy for prevention of CINV which is comparable to the efficacy reported from the studies evaluating with PAD regimen. If the efficacy of RAD regimen is evidently proven by this kind of randomized multicenter-trial, RAD regimen can be more recommended as a standard regimen for HEC-induced CINV.

02

Conditions studied

  • Cancer
  • Tumors

Keywords

  • ramosetron
  • palonosetron
  • chemotherapy induced nausea and vomiting
03

In context

Neoplasms

10,837 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 292 is above the median of 60 across 7,716 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Kangdong Sacred Heart Hospital is the lead sponsor of 6 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The patient's age is ≥ 19 years old
  • or cytologically confirmed solid tumor
  • Patients diagnosed as who will be treated with highly emetogenic chemotherapeutic agents (NCCN guideline v2.0, 2014 anti-emesis). (Cisplatin dosage is over 50mg/m2, combination therapy is available with other chemotherapeutic agents and including lymphoma)
  • (ECOG) performance status 0-2
  • Available oral administration of study drugs
  • Adequate organ functions as follows: 1) Hematologic - white blood cell count (WBC) ≥ 3000 microliter (microL) or Neutrophil≥ 1500 micro/L, ≥ 100,000/microL; 2) Serum Creatinine ≤ 1.5 times ; 3) Hepatic function - Total , , ALT ≤2.5 times upper limit of normal, ALP ≤ 2 times upper limit of normal( except ALP increasing due to bone
  • Patients with normal range of serum K, Mg and hold serum Ca over lower limit of normal range
  • Patients must sign an indicating that they are aware of the nature of the study in keeping with the policy of the hospital

Exclusion criteria

Exclusion Criteria:

  • Patients with severe Hypertension, severe Heart disease, congenital long syndrome, bradyarrhythmia severe kidney disease(serum creatinine≥3㎎/㎗), liver disease (, ALT ≥ 2.5 times of upper normal range, ALP ≥ 2 times of upper normal range)
  • Patients with GI obstruction, active gastric ulcer or other diseases that could provoke nausea and vomiting
  • Patients who have nausea and vomiting within 1 week before chemotherapy
  • Patients who should take , antiemetics, antipsychotic agent including benzodiazepine, pimozide, terfenadine, astemizole, cisapride, rifampin, carbamazepine, phenytoin, ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir or nelfinavir, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors for the treatment of other diseases
  • Patients with brain tumor, or seizure
  • Patients receiving chemotherapy within 6 months before enrollment
  • Patients who need radiation therapy during study period or receiving radiation therapy within 2 weeks before chemotherapy
  • Patients who have known allergy or severe side effect on study drugs(5-HT3 antagonist and aprepitant)
  • Pregnant or lactating women, or women who wish to become pregnant
  • Patients with drug abuse, a mental disease and difficult to communicate with investigators
  • Others whom the investigator judges inappropriate as subjects for this study
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 4
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
292 participants (actual)

Study arms

  • Experimental
    ramosetron, aprepitant, dexamethasone

    1. Ramosetron 0.3mg IV day1 2. Aprepitant 125mg PO qd day1, 80mg po qd day 2, 3 3. Dexamethasone 12mg IV or PO qd day1, 8mg PO day 2, 3, 4

    Drug: ramosetron, aprepitant, dexamethasone

  • Active comparator
    palonosetron, aprepitant, dexamethasone

    1. Palonosetron 0.25mg IV day1 2. Aprepitant 125mg PO qd day1, 80mg po qd day 2, 3 3. Dexamethasone 12mg IV or PO qd day1, 8mg PO day 2, 3, 4

    Drug: palonosetron, aprepitant, dexamethasone

Interventions

06

What researchers measure

Primary outcomes

  1. To compare the overall complete response (CR) of RAD to PAD (Overall CR defined as no emesis, no rescue medication, at cycle 1

    Time frame: 0-120 hours

07

Study locations

10 sites
  • St. Vincent'S Hospital
    Suwon, Gyeonggi 16247, Korea, Republic of
  • Keimyung University Dongsan Medical Center
    Daegu, Korea, Republic of
  • Chungnam National University Hospita
    Daejeon, Korea, Republic of
  • Pusan National University Hospital
    Pusan, Korea, Republic of
  • Kangbuk Samsung Hospital
    Seoul, Korea, Republic of
  • Kangdong Sacred Heart Hospital
    Seoul, Korea, Republic of
  • Samsung Medical Center
    Seoul, Korea, Republic of
  • Seoul St. Mary's Hospital
    Seoul, Korea, Republic of
  • Severance Hospital
    Seoul, Korea, Republic of
  • Ajou University Hospital
    Suwon, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2015 to primary completion in May 2018, 32 months.

Of 64 non-industry phase 4 interventional studies under Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 56. This study's 32 months is close to that.

Counting every sponsor, half of 88 studies reached it within 38 months; a quarter within 21 and three quarters within 64.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2015
First posted
Aug 26, 2015
StartActual
Aug 19, 2015
Primary completionActual
May 8, 2018
CompletionActual
May 8, 2018
Last update
May 11, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02532634
Lead sponsor
Kangdong Sacred Heart Hospital
Responsible party
Kwon, Jung Hye (Associate Professor, Kangdong Sacred Heart Hospital) — Principal investigator
First posted
Aug 26, 2015
Start date
Aug 19, 2015
Primary completion
May 8, 2018
Completion
May 8, 2018
Last update
May 11, 2018

Study contacts

Jin-Hyoung Kang, Ph.D
principal investigator · The Catholic University of Korea
Jung Hye Kwon, PhD
study director · Kangdong Sacred Heart Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ramosetron · Aprepitant · Dexamethasone

Start the discussion